Menu
Search
|

Menu

Close
X

Merrimack Pharmaceuticals Inc MACK.OQ (NASDAQ Stock Exchange Global Market)

5.47 USD
+0.11 (+2.05%)
As of Sep 13
Previous Close 5.36
Open 5.44
Volume 10,733
3m Avg Volume 10,829
Today’s High 5.56
Today’s Low 5.36
52 Week High 7.50
52 Week Low 3.35
Shares Outstanding (mil) 13.35
Market Capitalization (mil) 85.44
Forward P/E --
Dividend (Yield %) 1.50 ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-1.490
FY18
-4.547
FY17
-4.182
FY16
-12.369
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
--
7.90
Price to Book (MRQ)
vs sector
2.13
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.64
LT Debt to Equity (MRQ)
vs sector
0.00
12.61
Return on Investment (TTM)
vs sector
-87.87
12.69
Return on Equity (TTM)
vs sector
-87.97
17.13

EXECUTIVE LEADERSHIP

Gary Crocker
Chairman of the Board, President, Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer, Since 2019
Salary: $31,000.00
Bonus: --
Ellen Forest
Head of Human Resources, Since 2017
Salary: --
Bonus: --
Daryl Drummond
Head of Research, Since 2017
Salary: $263,376.00
Bonus: $99,393.00
George Demetri
Director, Since 2017
Salary: --
Bonus: --
Ulrik Nielsen
Director, Since 2015
Salary: $384,324.00
Bonus: $136,423.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1 Broadway Fl 14
CAMBRIDGE   MA   02142-1187

Phone: +1617.4411000

Merrimack Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing novel treatments for cancer by targeting biomarker-defined cancers. Its clinical programs include MM-121 (seribantumab), MM-141 (istiratumab) and MM-310. MM-121 is a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1, or IGF-1, receptor and ErbB3 (HER3) cell surface receptor. MM-310 is an antibody-directed nanotherapeutic that targets the ephrin receptor A2, or EphA2, receptor and contains a novel prodrug of the highly potent chemotherapy docetaxel. The Company’s preclinical programs include MM-161, ATRi, BCL2/BCLxl, TRAIL, Immuno-oncology and STIMULI.

SPONSORED STORIES